Other News To Note
• Addex Pharmaceuticals Ltd., of Geneva, reported data showing that orally available candidate GLP1R PAM increased insulin secretion and decreased glycemia in response to glucose in preclinical models of diabetes. In the "db/db" model, in which insulin response to oral glucose in muted, GLP1R PAM (positive allosteric modulator) facilitated an insulin response and better control over blood glucose than vehicle or a marketed drug to treat Type II diabetes.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter